Results 91 to 100 of about 2,655 (208)

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment—A Case Report

European Journal of Neurology, Volume 33, Issue 2, February 2026.
A 64‐year‐old man was admitted to the stroke unit with acute aphasia and right‐sided hemiplegia, but imaging showed no signs of acute stroke. Symptoms gradually improved and fully resolved by Day 21, following the onset of a hemicranial headache. A diagnosis of sporadic hemiplegic migraine was made, and no further attacks occurred under fremanezumab ...
Julian Frederic Hotz, Lisa Kaindl, Stefan Krebs, Marion Vigl, Julia Ferrari, Christian Neumann, Robert Han, Lavinia Ritscher, Marek Sykora, Paolo Gallmetzer   +9 more
wiley   +1 more source

Migren Profilaksisinde Etkili Bir Ajan; Galcanezumab: Tek Merkez Deneyimleri

Sakarya Tıp Dergisi
Giriş: Migren, tipik olarak 4 ile 72 saat süren, genellikle orta veya şiddetli tekrarlayan başağrısı atakları ile karakterizedir. Başağrısı, genellikle bulantı, kusma ve/veya ışığa ve sese karşı tahammülsüzlük ile birlikte görülür.
Sena Boncuk Ulaş, Ayşe Polat Zafer, Türkan Acar, Levent Avcı   +3 more
doaj   +1 more source

Galcanezumab in the prophylaxis of migraine [PDF]

Pharmacotherapy in Psychiatry and Neurology, 2020
The aim of preventive treatment of episodic and chronic migraine is to reduce the frequency and severity of seizures and thereby improve the quality of patients' lives. It is estimated that 38% of patients with migraine would benefit from preventive treatment.
openaire   +1 more source

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study

Patient Preference and Adherence, 2022
Oralee J Varnado,1 Janna Manjelievskaia,2 Wenyu Ye,1 Allison Perry,2 Kory Schuh,1 Richard Wenzel1 1Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; 2Watson Health Life Sciences, Research & Analytics, IBM Watson Health ...
Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R   +5 more
doaj  

COMPARISON OF EFFICACY AND SAFETY OF NEWER DRUGS APPROVED FOR THE TREATMENT OF MIGRAINE DISORDER: A REVIEW [PDF]

, 2020
Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea and weakness symptoms.
CHEW, TENG TENG, GOVINDARAJAN, ARULKUMARAN, KRISHNASAMY, KARTHIKAYINI, LAU, NATALIE JIA XIN, MEETOOA, BIBI MUNIIRAH UMMEH HAANI, NG, ELAINE, ONG, MICHELLA, ROSMAN, AIDIL NATASHA, SHANMUGASUNDARAM, AKILA, SHAPHERI, AINAA DIYANA, SIVANANDY, PALANISAMY, YEONG, MICHELLE ZI YIN   +11 more
core   +1 more source

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study

Patient Preference and Adherence
Oralee J Varnado,1 Brenna L Brady,2 Anthony J Zagar,1 Yvonne P Robles,2 Margaret Hoyt1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Merative, Ann Arbor, MI, USACorrespondence: Oralee J VarnadoValue, Evidence, and Outcomes, Eli Lilly and Company, Lilly
Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M   +4 more
doaj  

Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments

The Journal of Headache and Pain
Objective To present the first Brazilian real-world results with galcanezumab and provide a consensus expert opinion on the prophylactic treatment of cluster headache (CH) in Brazil.
Abouch Krymchantowski, Carla Jevoux, Élcio Juliato Piovesan, Marcelo Moraes Valença, Fernando Kowacs, Pedro André Kowacs, Fabíola Dach, Paulo Hélio Monzillo, Carlos Alberto Bordini, Raimundo Pereira Silva-Néto   +9 more
doaj   +1 more source

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

Journal of Pain Research, 2021
J Scott Andrews,1 David Kudrow,2 Mallikarjuna Rettiganti,1 Tina Oakes,1 Jennifer N Bardos,1 Richard Wenzel,1 Dulanji K Kuruppu,1 Charly Gaul,3 James M Martinez1 1Eli Lilly and Company, Indianapolis, IN, USA; 2California Medical Clinic for Headache, Santa
Andrews JS, Kudrow D, Rettiganti M, Oakes T, Bardos JN, Wenzel R, Kuruppu DK, Gaul C, Martinez JM   +8 more
doaj  

Chilblains after galcanezumab for chronic migraine prevention: A case report

Cephalalgia Reports
Background Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are effective migraine prophylactics but real-world safety data is still emerging. This is the first case of chilblains associated with galcanezumab.
Lakshini Gunasekera, Jason C Ray
doaj   +1 more source